Drug Profile
Research programme: pain therapeutics - Bionomics/Merck
Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Bionomics; Merck & Co
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors; Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 01 Dec 2022 Preclinical trials in Pain in Australia (unspecified route) (Bionomics pipeline, December 2022)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Pain in Australia
- 11 Dec 2019 Preclinical development is ongoing in Australia